SHINE to supply n.c.a. Lu-177 for the clinical development of Telix’s investigational radiopharmaceuticals, TLX591 and TLX250

JANESVILLE, Wis., Feb. 10, 2022 – SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, and Telix Pharmaceuticals LTD (Telix), a biopharmaceutical company headquartered in Australia, today announced the signing of a clinical supply agreement that provides Telix with SHINE’s non-carrier-added (n.c.a.) lutetium-177 (Lu-177) for use in the clinical development of potential new therapeutics to treat prostate and kidney cancer.

SHINE will immediately commence supply of n.c.a. Lu-177 for use in clinical trials of Telix’s therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuximab for kidney cancer), with particular focus on the US market.

“There continues to be a growing, critical need for more effective treatment of metastatic or late-stage cancers,” said Greg Piefer, SHINE’s founder and CEO. “Our exciting partnership with Telix allows us to bring hope to these patients as we continue to help deliver Lu-177 for highly precise treatments that produce little damage in the tissue around treatment sites.”

SHINE’s Therapeutics division produces n.c.a. Lu-177, a low-energy beta-particle emitter, which can be paired with a targeting molecule (such as an antibody or peptide) to directly target and irradiate cancer cells. Several Lu-177 therapies are currently being developed to treat various forms of cancer and may provide alternative treatment options for patients where other therapeutic solutions have proven insufficient.

Dr. Gabriel Liberatore, Telix Group Chief Operating Officer continued, “SHINE’s investment in high quality isotope production places them at the forefront of the radiopharmaceutical supply chain with particular strength in servicing the US market. The agreement with SHINE supports our goal to establish a global supply chain with the capacity and reliability to support an increasing level of clinical activity through Telix-sponsored and investigator-led studies and to scale-up to commercial stage.”

About SHINE Technologies
SHINE is a next-generation nuclear technology company focused on deploying state-of-the-art fusion technology to help solve global problems as a scalable path to practical fusion energy. SHINE’s nuclear technology and proprietary isotope production process produces n.c.a. Lu-177 that does not contain impurity byproducts, such as the metastable Lu-177m. Without these impurity byproducts, n.c.a. Lu-177 is a stronger therapeutic concentration of medically useful radioisotopes and produces less radioactive post-procedure medical waste than carrier-added Lu-177. For more information, follow SHINE on Facebook, LinkedIn and Twitter.

About Telix Pharmaceuticals
Telix is a biopharmaceutical company, headquartered in Melbourne, Australia with international operations in Belgium, Switzerland, Japan, and the United States, focused on the development and commercialization of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). For more information visit www.telixpharma.com.

Contacts:

SHINE Technologies
Patrick O’Connell
VP, Marketing & Communications
+1.317.374.4960
Patrick.OConnell@shinefusion.com

Telix Pharmaceuticals
Kyahn Williamson
SVP Corporate Communications and Investor Relations
Kyahn.williamson@telixpharma.com